🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Current APS diagnosis often requires the cessation of anticoagulation therapy in patients who experienced thrombosis. ow.ly/YwwU50QHi14 #thrombosisandhemostasis

Welcome to our incredible incoming intern class of 2024!! We are so excited for this amazing group of doctors to join us this summer 🥳🎉

Join us in welcoming Klaus Mäkelä as the 11th music director of the Chicago Symphony Orchestra! Learn more: cso.org/klausmakela youtu.be/XgQJFH9d5eQ?si…

ASH was thrilled to host our inaugural HFFTP class, embodying excellence across all regions. Their unique stories & passion for hematology enrich our journey. ASH's $19M investment in innovative US medical education is already making history! Learn more: ow.ly/8N6150RcXyL

🩸 Are you a resident getting ready to apply for fellowship or a #medstudent interested in learning more about #hematology? Learn more about ASH HFFTP & talk with current fellows at the informational webinar on June 10 at 6:30 p.m. ET: ow.ly/jURM50RPPjA #ASHTrainee #MedEd

I just learned about a Japanese idea I can’t stop thinking about… What it is and how it can change your life:

In cancer, not all platelets are created equal ow.ly/XqvT50SzQ7N #plateletsandthrombopoiesis

Thrombosis in atypical sites is often the first sign of PNH, and anticoagulation/anticomplement combination is the mainstay of treatment. ow.ly/vlRE50SzRHU #clinicaltrialsandobservations

#MassGeneral physician Sharl Azar, MD, Sharl Azar, MD received the Distinguished Service Award from Massachusetts Sickle Cell Association. He also received the Walter C. Reynolds Community Service Award from OHSU News for his commitment and service to diversity, equity and inclusion.

New @ISTH guidance on anticoagulation for AF, DVT/PE and PVT in patients with cirrhosis from the SSC. Want to know who to treat, when to use a DOAC and more? Click jthjournal.org/article/S1538-… McMaster University Department of Medicine Virginia @Gendronnico Deborah Siegal @LaraNRoberts1 Alexander Gatt

Very interesting study. There is significant institutional variation on applications of D-dimer for personalized anticoagulation duration, and these results further contribute to the dialogue.

The therapeutic landscape of #ITP treatments is expanding rapidly. If you want to be updated about what is coming, this is a great article discussing the clinical trials of the main products in development. tinyurl.com/4377d9k9

Tune in for a cool case!

🩺 Are you a resident or med student wondering which fellowship to apply for? Consider the ASH HFFTP! This program supports 10 #hematology-focused fellowship tracks within existing programs at 9 ACGME accredited institutions. Learn more & apply: ow.ly/WUfV50SGjh4 #MedEd

We’re excited about our upcoming webinar on “Factor XI/XIa Inhibition: Ensuring Safety and Efficacy” 🔬 Don’t miss this opportunity to dive into the latest insights on Factor XI/XIa inhibition: bit.ly/3U42Cif

JAKi in patients with myelofibrosis 2024 ashpublications.org/blood/article-…

1/ FDA hearing on #andexanet alfa is tomorrow (21 Nov 2024). The documents contain some more data on thrombotic events that weren't published in ANNEXA-I. To be honest, reading through, I have found this data pretty shocking. A 🧵

The legendary Berlin Philharmonic Orchestra performing Bruckner’s 5th in Boston’s Symphony Hall…a divine cathedral of sound.

Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation: NEJM 🥸Summary 👇👇👇

In this BJH In a Nutshell article, Drs. Song and Al-Samkari bring you up to date on the status of research in chemotherapy-induced thrombocytopenia and how to treat this common problem with TPO-RAs. buff.ly/H4QU0fo Hanny Al-Samkari, MD Andrew Song